
Senior Scientist @AstraZeneca interested in understanding mechanisms of resistance to cancer immunotherapy.
Cambridge, England
Joined October 2015
- Tweets86
- Following587
- Followers85
- Likes576
Reda retweeted
New #JITC article: "Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy" jitc.bmj.com/content/14/5/e0…
@kalender_atak @imartincorena @AdamJSchoenfeld @AstraZeneca
Reda retweeted
Only few places left!
🧐 Next Cam Comp Onco meeting
⏲️ March 15th, 3-6 pm
🛖 hosted by AZ at the DISC
📢 @OMRueda @AppleTreeWoman @RedaKeddar
❗️❗️Register by march 10th❗️❗️
forms.office.com/e/iRW1Eak3t…
Reda retweeted
Miriam Merad, MD, PhD, Elected to the National Academy of Medicine for Seminal Work in Immunology and Cell Biology | Mount Sinai - New York shar.es/agmF0C
@IcahnMountSinai @SinaiImmunol @theNAMedicine
Reda retweeted
Nature research paper: Y chromosome loss in cancer drives growth by evasion of adaptive immunity go.nature.com/46iUGhu
Reda retweeted
Thrilled to begin my tenure as the new president of @iuis_online! We are working toward demystifying immunology research, fostering global collaborations & bringing new immunotherapies to patients everywhere 🤝
Read more here: iuis.org/about/who-we-are/ed…
Reda retweeted
'Mechanisms driving the immunoregulatory function of cancer cells' nature.com/articles/s41568-0…
Reda retweeted
After a break from Twitter, I am happy to post @hrvshrvs and @RedaKeddar tour the force to understand how cancer genes impact on and are impacted by nearby immune cells. Great clinical insights from @JPJeannon. 🙏 to @CRUKresearch and @GSTTCharity. 👇🏽 biorxiv.org/content/10.1101/…
Reda retweeted
Very proud to be inducted today along incredible scientists @theNASciences and very grateful to many people and institutions that led me here. Starting with my Med school mentors in Algiers including my parents who taught me intellectual engagement , discipline & rigor (1/x)
Reda retweeted
Can we break the glass ceiling of PD1/PDL1 inhibition? In the #COAST phase 2 trial, stage III NSCLC pts were randomized after CT/RT to durvalumab +/- oleclumab (anti-CD73) or monalizumab (anti-NKG2A). Both study arms showed doubled ORR & prolonged PFS.
ascopubs.org/doi/abs/10.1200…
Reda retweeted
This is a tour de force and transformative study led by @MaximeDhainaut and Brian Brown @SinaiImmunol describing a spatial CRISPR genomics screen to identify regulators that drive cell composition and spatial organization in the tumor microenvironment cell.com/cell/fulltext/S0092…
Reda retweeted
Dressler, Bortolomeazzi,@RedaKeddar, Misetic, Sartini, @AmeAchaSag, Montorsi, @fcicca & co present the 6th update of the Network of Cancer Genes database. It contains 3355 well-known or predicted cancer drivers, but shows there are still unknown drivers genomebiology.biomedcentral.…
Reda retweeted
Struggling with multiplexed imaging data from IMC, CODEX, MIBI, cycIF? So were we… until Michele, @RedaKeddar, Damjan, @AmeAchaSag and Lucia in the lab developed a SIMPLI method for spatially resolved tissue phenotyping at single cell resolution Preprint👇🏾biorxiv.org/content/10.1101/…
Reda retweeted
In patients with microsatellite-unstable colorectal tumors, pembrolizumab led to longer progression-free survival and was less toxic than standard care.
Reda retweeted
Replying to @RedaKeddar
@RedaKeddar from our lab presenting the results of out profile of immune and cancer cells in response to immunotherapy @TheCrick @KCLcancer_pharm @ITN_CONTRA @CR_UK #CrickCancerConf
Reda retweeted
Excited to join Twitter by sharing our latest paper on human B cell development in collaboration with @BemarkMats @KCLImmunoMicro @GSTTresearch biorxiv.org/content/10.1101/…
Reda retweeted
KEYNOTE-158 study out in Lancet Oncology, Pembrolizumab for TMB>10- most data time date we have seen since FDA approval, key aspects include tumor types studied thelancet.com/journals/lanon…
Reda retweeted
Still a few days to apply and work with us @TheCrick @KCLcancer_pharm @CRUKresearch. Details below 👇 Pls spread the word and RT. 🙏🏽 jobs.kcl.ac.uk/gb/en/job/004…
Reda retweeted
CRI scientist Dr. Hiroyoshi Nishikawa of Japan National Cancer Center revealed how a single mutation can reprogram the tumor microenvironment in a way that favors the metabolism and activity of immune-suppressing Tregs. cell.com/immunity/fulltext/S…
Reda retweeted
Interested to see how the forthcoming data behind the ‘TMB > 10 in all cancer types’ approval addresses a few key issues, having spent a long time thinking about this general topic - some thoughts to follow:
[1/n]
Reda retweeted
New issue online! cell.com/immunity/issue?pii=… Cover from @MartinGuilliams, Thierry, Bonnardel, & @BajenoffL on their review of the #macrophage niche. Art by Sigrid Knemeyer & Matt Crotts (SciStories). Includes a trio of Reviews on interactions of immune & non-immune cells in tissues!























